3 Australian Growth Stocks With Revenue Growth Over 21%

Global markets have been shaken by fresh concerns about inflation and geopolitics, and that is where high growth Australian companies with clear plans and confident management teams can get interesting. Volatility often punishes everything at once. Strong businesses with credible growth ambitions can be left trading on terms that look appealing. This article highlights three high conviction growth stocks from this focused screener.

The stocks profiled below are just a small sample, and the full High Growth High Conviction screen surfaced 23 more companies with equally compelling stories that are not covered here.

To identify ideas that fit your own risk appetite and time horizon, head straight into the High Growth High Conviction screener to filter and analyze the highest conviction opportunities on your terms.

Emerald Resources (ASX:EMR)

Overview: Emerald Resources is an Australian minerals group focused on gold, led by its 100% owned Okvau Gold Project in Cambodia.

Operations: Emerald Resources generates about A$602 million from Mine Operations and A$11 million from Other activities, with roughly A$609 million earned in Cambodia.

Market Cap: A$3.83b

Emerald Resources aligns with the High Growth High Conviction theme, with earnings rising sharply in 2026 and revenue of A$612.32 million supported by the Okvau Gold Project. Forecast double digit earnings and revenue growth give that project additional significance. The current appeal depends on how one unseen pressure affects future margins and funding headroom.

That pressure point is exactly what the Emerald Resources financial health report unpacks, so you can see how Emerald Resources’ balance sheet might absorb swings in gold prices and costs.

Mesoblast (ASX:MSB)

Overview: Mesoblast develops regenerative medicine therapies using mesenchymal lineage cells to treat severe inflammatory, cardiovascular, and orthopedic conditions.

Operations: Mesoblast currently records about $120 million in revenue from development and commercialization of its allogeneic cellular medicines platform.

Market Cap: A$2.30b

Mesoblast fits into the High Growth High Conviction theme through late stage cell therapy programs that management states are intended to reshape its earnings profile.

"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption."

Mesoblast’s valuation and cash requirements depend on the pace of broader adoption and the timing of subsequent trial results.

That adoption curve is only part of the story, and the full narrative for Mesoblast maps how Mesoblast’s risk, pricing power, and potential inflection points could be decoupling from headline trial results.

Pinnacle Investment Management Group (ASX:PNI)

Overview: Pinnacle Investment Management Group partners with boutique fund managers, providing distribution, fund infrastructure, and trustee services that scale high conviction investment strategies.

Operations: Pinnacle generates about A$110 million from funds management operations, almost entirely sourced from clients in Australia.

Market Cap: A$3.36b

Pinnacle Investment Management Group matters for this High Growth High Conviction screen because its multi affiliate platform is built to spread high conviction fund managers across a larger investor base, turning specialist strategies into a broader fee pool.

"Expansion of international affiliates and clients, with about one third of A$229.4 billion of affiliate FUM now sourced outside Australia and A$75 billion coming from more than 50 countries, can deepen diversification and support a larger revenue base as offshore fee streams build."

The key variable is how the evolving mix between recurring fees and more volatile performance revenue ultimately filters through to Pinnacle’s earnings quality.

If you want to see how that fee mix could be accelerating or masking Pinnacle Investment Management Group’s earnings quality story, read the full narrative for Pinnacle Investment Management Group for the full picture.

Seeking Alternatives Before The Crowd

Fresh ideas move first, then prices follow. Spot the quiet momentum, the potential breakout, the stories still under the radar for now. Act now.

• Target resilient income streams by scanning the 6 dividend fortresses and see which cash generators might keep paying out even when sentiment turns.
• Hunt for future AI leaders with the 55 AI infrastructure stocks and review which enablers could sit behind the next leg of computing demand.
• Track the energy transition story through the 16 top copper producer stocks and assess which producers are positioned for long term electrification demand.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com